Uloric is an anti-gout drug owned by Takeda Pharms Usa. The drug was first authorized for market use on 13 February, 2009. Its active ingredient is febuxostat and it is available in a tablet; oral dosage form.
The generic version of Uloric could be released after 08 September, 2031. This date accounts for all of Uloric's current patents, with the last one expiring on 08 September 2031 due to the 'Methods for concomitant treatment of theophylline and febuxostat' patent.
Uloric contains febuxostat which can be used for the management of hyperuricemia in patients suffering from gout. Uniquely, Uloric can be used in conjunction with theophylline without the need for dose adjustment of theophylline.
Uloric, with its generic likely to be launched post 08 September, 2031, has a total of 3 active patents. The latest patent, 'Methods for concomitant treatment of theophylline and febuxostat,' will expire on that date. Below are the details of the patent: